STO-609 | CAMKK inhibitor
NMR (Conforms)
Available Options
| Size: | Price | Quantity | |
|---|---|---|---|
| 5 mg | $75.00 | ||
| 25 mg | $290.00 |
STO-609 (1173022-21-3) is a selective inhibitor of Ca2+-calmodulin-dependent protein kinase kinase (Ki = 80 and 15 ng/ml for inhibition of CaM-KKα and CaM-KKβ respectively).1 Binds to the ATP-binding site.2 Displays > 80-fold selectivity over CaMK1, CaMK2, CaMK4, MLCK, PKC, PKA and p42 MAPK. Important tool for probing distinct CaMK pathways in LTP.3 Reduces starvation-induced autophagosomal membrane formation.4 Reverses age-associated decline in bone mass.5 Stimulates osteoblast formation, inhibits osteoclast differentiation.6
References/Citations:
1) Tokumitsu et al. (2002), STO-609, a Specific Inhibitor of the Ca2+/Calmodulin-dependent Protein Kinase Kinase; J. Biol. Chem. 277 15813
2) Tokumitsu et al. (2003) A single amino acid difference between alpha and beta Ca2+/calmodulin-dependent protein kinase kinase dictates sensitivity to the specific inhibitor, STO-609; J. Biol. Chem. 278 10908
3) Redondo et al. (2010) Synaptic tagging and capture: differential role of distinct calcium/calmodulin kinases in protein synthesis-dependent long-term potentiation; J. Neurosci. 30 4981
4) Pfisterer et al. (2011) Ca+2/calmodulin –dependent kinase (CaMK) signaling via CaMKI and AMP-activated protein kinase contributes to the regulation of WIPI-1 ar the onset of autophagy; Mol. Pharmacol. 80 1066
5) Pritchard et al. (2015) Inhibition of CaMKK2 reverses age-associated decline in bone mass; Bone, 75 120
6)Cary et al. (2013) Inhibition of Ca+2/Calmodulin-dependent protein kinase kinase 2 stimulates osteoblast formation and inhibits osteoclast differentiation; J. Bone Miner. Res. 28 1599
7) Matsukawa et al. (2017) Upregulation of skeletal muscle PGC-1α through the elevation of cyclic AMP levels by Cyanidin-3-glucoside enhances exercise performance; Sci. Rep., 7 44799
NMR (Conforms)
Safety Data Sheet:
Product Data Sheet:
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
STO-609 (1173022-21-3) is a selective inhibitor of Ca2+-calmodulin-dependent protein kinase kinase (Ki = 80 and 15 ng/ml for inhibition of CaM-KKα and CaM-KKβ respectively).1 Binds to the ATP-binding site.2 Displays > 80-fold selectivity over CaMK1, CaMK2, CaMK4, MLCK, PKC, PKA and p42 MAPK. Important tool for probing distinct CaMK pathways in LTP.3 Reduces starvation-induced autophagosomal membrane formation.4 Reverses age-associated decline in bone mass.5 Stimulates osteoblast formation, inhibits osteoclast differentiation.6
References/Citations:
1) Tokumitsu et al. (2002), STO-609, a Specific Inhibitor of the Ca2+/Calmodulin-dependent Protein Kinase Kinase; J. Biol. Chem. 277 15813
2) Tokumitsu et al. (2003) A single amino acid difference between alpha and beta Ca2+/calmodulin-dependent protein kinase kinase dictates sensitivity to the specific inhibitor, STO-609; J. Biol. Chem. 278 10908
3) Redondo et al. (2010) Synaptic tagging and capture: differential role of distinct calcium/calmodulin kinases in protein synthesis-dependent long-term potentiation; J. Neurosci. 30 4981
4) Pfisterer et al. (2011) Ca+2/calmodulin –dependent kinase (CaMK) signaling via CaMKI and AMP-activated protein kinase contributes to the regulation of WIPI-1 ar the onset of autophagy; Mol. Pharmacol. 80 1066
5) Pritchard et al. (2015) Inhibition of CaMKK2 reverses age-associated decline in bone mass; Bone, 75 120
6)Cary et al. (2013) Inhibition of Ca+2/Calmodulin-dependent protein kinase kinase 2 stimulates osteoblast formation and inhibits osteoclast differentiation; J. Bone Miner. Res. 28 1599
7) Matsukawa et al. (2017) Upregulation of skeletal muscle PGC-1α through the elevation of cyclic AMP levels by Cyanidin-3-glucoside enhances exercise performance; Sci. Rep., 7 44799
Related products
-
Isradipine | L-type Ca channel blocker
From $64.00CAS:75695-93-1Catalog Number:10-1202Activity:L-type Ca channel blockerChemical Name:4-(4-Benzofurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid, methyl, 1-methylethyl diesterMolecular Weight:371.4Molecular Formula:C19H21N3O5Solubility:Soluble in DMSO (up to 25 mg/ml) or in Ethanol (up to 15 mg/ml).Physical Properties:Yellow solidPurity:99% by TLC
NMR (Conforms)Storage Temperature:RTStability:Stable for 2 years from date of purchsae as supplied. Protect from moisture. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months.Shipping Code:RT -
Verapamil HCl | L-type Ca channel blocker
From $27.00CAS:152-11-4Catalog Number:10-1111Activity:L-type Ca channel blockerChemical Name:5-[N-(3,4-Dimethoxyphenylethyl)methylamino]-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile hydrochlorideMolecular Weight:491.06Molecular Formula:C27H38N2O4·HClSolubility:Soluble in DMSO (up to 20 mg/ml) or in Water (up to 50 mg/ml).Physical Properties:White solidPurity:>98% by TLCStorage Temperature:RTStability:Stable for 2 years from date of purchase as supplied. Solutions in DMSO or distilled water may be stored at -20°C for up to 3 months.Shipping Code:RT -
Nifedipine | L-type Ca channel blocker
From $40.00CAS:21829-25-4Catalog Number:10-1116Activity:L-type Ca channel blockerChemical Name:2,6-Dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid dimethyl esterMolecular Weight:346.34Molecular Formula:C17H18N2O6Solubility:Soluble in DMSO (up to 25 mg/ml).Physical Properties:Yellow solidPurity:98% by TLC
NMR (Conforms)Storage Temperature:RTStability:Stable for 1 year from date of purchase as supplied. Solutions are not stable and must be used within one working day.Shipping Code:RT
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
Focus Biomolecules • Plymouth Meeting, PA USA • 1-855-FOCUS21
Focus Biomolecules
Plymouth Meeting, PA USA
1-855-FOCUS21
Website Created by Advanta Advertising LLC.